Another research showed that ginsenoside Rg1 can downregulate cyclin-dependent kinase 5 (CDK5) expression to inhibit the phosphorylation of PPARγ and the activity of its targets, BACE and insulin-degrading enzyme (IDE), reducing Aβ levels, and exerting neuroprotective effects against AD (Quan et al., 2020). Here, IDE is linked to Alzheimer disease.